L ccg 1

Aminoguanidine hydrochloride, copper(II) sulfate (CuSO₄), (+)-sodium l-ascorbate, tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine, THPTA, l-glutamate, and chemicals used for synthesis were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless stated otherwise. LY379268, LY354740, DCG-IV, L-CCG-I, and BINA were purchased from Tocris Bioscience (Bristol, UK). O⁶-benzylguanine and amine derivatives of Lumi4-Tb, green (fluorescein derivative), red (DY647 derivative) fluorophores, as well as Tag-lite buffer were from PerkinElmer (Codolet, France). 4-PrF was initially synthesized according to (31 (link)) and later purchased from Iris Biotech GmbH (Marktredwitz, Germany). BTTAA was synthesized as described in (40 (link)). pAz-Lumi4-Tb, pAz-green, and pAz-red were synthesized as described in the Supplementary Protocol. pAz-AF488, pAz-AF546, and pAz-AF647 were purchased from Jena Bioscience (Jena, Germany). LMNG and CHS tris salt were purchased from Anatrace (through CliniSciences, France). GDN was purchased from Avanti Polar Lipids through Merck.

All chemicals were purchased from Sigma-Aldrich, Merck and Roth unless otherwise noted. n-dodecyl-β-D-maltopyranoside (DDM), lauryl maltose neopentyl glycol (LMNG), and cholesteryl hemisuccinate (CHS) tris salt were purchased from Anatrace (through CliniSciences, France). Glyco-diosgenin (GDN) was purchased from Avanti Polar Lipids through Merck. SNAP-Lumi4-Tb, SNAP-green, SNAP-Cy3B, and SNAP-d2 were obtained from Cisbio Bioassays (Codolet, France). DCG-IV, LY341495, LY379268, LY354740, LCCG-I, BINA hydrochloride, and Ro64-5229 were purchased from Tocris Bioscience (Bristol, UK).